BTL-HM401-100μg / 询价
BTL-HM401-500μg / 询价
BTL-HM401-500μgx2 / 询价
Human BTLA Protein
Recombinant Human BTLA Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Lys31-Ser150.[Accession | Q7Z6A9-1]
The protein has a predicted MW of 16.7 kDa. Due to glycosylation, the protein migrates to 35-45 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human BTLA on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of Human BTLA is greater than 95% as determined by SEC-HPLC.
Immobilized Human BTLA, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-BTLA Antibody, hFc Tag with the EC50 of 5.0ng/ml determined by ELISA (QC Test).
Immobilized Human BTLA, His Tag at 1μg/ml (100μl/Well). Dose response curve for Human HVEM, hFc Tag with the EC50 of 42.5ng/ml determined by ELISA.
Anti-BTLA antibody captured on Protein A chip, can bind Human BTLA, His Tag with an affinity constant of 0.99nM as determined in a SPR assay (Biacore T200).
B- and T-lymphocyte attenuator (BTLA; CD272) is a 35 kDa type I transmembrane glycoprotein in the CD28 family of T cell costimulatory molecules. BTLA is a inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. BTLA may interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14.
CD272; BTLA; BTLA1; FLJ16065; MGC129743
(1)Haymaker C L , Wu R C , Ritthipichai K , et al. BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties[J]. OncoImmunology, 2015, 4(8):e1014246.
